Vyndaqel and Vyndamax (tafamidis) are Pfizer's oral transthyretin stabiliser capsules for ATTR cardiomyopathy, stored at room temperature, with two strengths that are not interchangeable mg for mg.

We do not publish prices, so we cannot give a Vyndamax 61 mg price or a Vyndaqel cost here. The landed cost of tafamidis depends on which brand and strength your registration names (Vyndaqel 20 mg, Vyndaqel 61 mg or Vyndamax 61 mg), the pack size, the quantity, the destination's registration route, the Incoterms and the freight lane. Both products are stored at room temperature, so there is no refrigerated freight line, but a tender may still ask for shelf-life and batch documents. M Care Exports quotes per destination once you send the brand, strength, volume and country.

On the FDA label, both are transthyretin stabilisers for ATTR-CM in adults. Vyndaqel is tafamidis meglumine 20 mg capsules, dosed at 80 mg as four capsules once daily. Vyndamax is tafamidis 61 mg capsules, dosed as one capsule once daily. The label says they are not substitutable on a per mg basis. Drugs@FDA lists US Vyndaqel as discontinued and Vyndamax as a prescription product. In the EU there is no separate Vyndamax name: the 20 mg capsule (tafamidis meglumine) and the 61 mg capsule (tafamidis) are both Vyndaqel, with different indications. This is a comparison of label facts, not a recommendation. Your prescriber and your registered label decide which product is used.

Per the EU SmPC, Vyndaqel 20 mg soft capsules contain 20 mg of tafamidis meglumine, equivalent to 12.2 mg tafamidis, and are indicated for adults with stage 1 symptomatic transthyretin polyneuropathy, at 20 mg once daily. Vyndaqel 61 mg soft capsules contain 61 mg of tafamidis and are indicated for wild-type or hereditary transthyretin amyloidosis in adults with cardiomyopathy. The same SmPC document also lists a 61 mg film-coated tablet, indicated for wild-type transthyretin amyloidosis in adults with cardiomyopathy. In the US, the FDA label lists only the cardiomyopathy indication, for Vyndaqel 20 mg and Vyndamax 61 mg. Check which indication your destination's registration carries before you order.

The generic name is tafamidis (tafamidis meglumine for the 20 mg product), and the class is a transthyretin stabiliser. In the EU, the EMA lists Tafamidis Accord (Accord Healthcare S.L.U.) as a generic of Vyndaqel, with a CHMP opinion on 23 July 2026 and an EU marketing authorisation issued on 18 September 2026, for hereditary ATTR cardiomyopathy. For the US, we have not confirmed an FDA-approved generic from a fetched FDA source, so check the FDA Orange Book for the current position. For India we have no regulator source to cite, so we state no position. We do not claim any generic is registered in your destination.

In the US, Drugs@FDA lists Vyndaqel (tafamidis meglumine 20 mg capsules) as discontinued, and the DailyMed listing gives a marketing end date of 31 July 2027 for the 120-capsule carton. Vyndamax 61 mg remains listed as a prescription product. In the EU, the EMA lists Vyndaqel, in both the 20 mg and 61 mg strengths, as authorised. Availability can differ by market and pack, and the EU SmPC notes that not all pack sizes may be marketed. Tell us the brand, strength and destination, and we confirm current supply before quoting.

No. The FDA label sets storage at 20 to 25 °C, with excursions permitted to 15 to 30 °C. The EU SmPC lists no special precautions for the 61 mg capsule, and not above 25 °C for the 20 mg capsule, with a 2-year shelf life. Pfizer is the originator: the FDA label directs reports to Pfizer Inc., and the EU marketing authorisation holder is Pfizer Europe MA EEIG. M Care Exports is a merchant-exporter and does not manufacture. We supply the finished product against your specification and check remaining shelf life and batch documents for each shipment.